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Abstract: We employed two selective EGFR tyrosine kinase inhibitors: AG494 (reversible) and AG1478 (irre-
versible) for growth regulation of human lung (A549) and prostate (DU145) cancer cell lines, cultured in chem-
ically defined DMEM/F12 medium. Both tested tyrphostins significantly inhibited autocrine growth of the in-
vestigated cell lines. The action of AG494 was dose dependent, and at highest concentrations led to complete
inhibition of growth. AG1478 seemed to be more effective at lower concentrations, but was unable to complete-
ly inhibit growth of A549 cells. Inhibition of EGFR kinase activity by AG494 in contrast to AG1478 had no effect
on the activity of ERK in both cell lines. Both EGFR’s inhibitors induced apoptosis of the investigated lung and
prostate cancer cell lines, but the proapoptotic effect of the investigated tyrphostins was greater in A549 than in
DU145 cells. The tyrphostins arrested cell growth of DU145 and A549 cells in the G1 phase, similarly to other
known inhibitors of EGFR. The influence of AG494 and AG1478 on the activity of two signaling proteins (AKT
and ERK) was dependent upon the kind of investigated cells. In the case of DU145 cells, there was an evident
decline in enzymatic activity of both kinases (stronger for AG1478), while in A549, only AG1478 effectively
inhibited the phosphorylation of Akt. Tyrphostins AG494 and AG1478 are ATP-competitors and are supposed
to have a similar mechanism of action, but our results suggest that this is not quite true. (Folia Histochemica et
Cytobiologica 2012, Vol. 50, No. 2, 186–195)
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Introduction
Lung and prostate cancer are the commonest causes
of death among all malignant carcinomas in the world,
because they are mainly diagnosed in advanced and
refractory stages of the disease. An important early
event in the development of the neoplastic pheno-
type is the induction of genes involved in autocrine
growth regulation, such as growth factors and their
receptors. An increased production of transforming
growth factor a (TGFa) or epidermal growth factor
(EGF) and its receptor (EGFR) involved in autocrine
regulation of cell growth has been found in several
lung and prostate cancer cell lines, including A549
and DU145 [1, 2]. Irregular downstream signaliza-
tion is a crucial factor in cancer development and
progression, because it controls proliferation, apo-
ptosis, angiogenesis, tumor invasiveness and me-
tastasis [3] and even drug resistance or response to
radiotherapy [4, 5].
Therefore, the family of EGFs receptors emerges
as an attractive target in anti-cancer therapy. One of
the most promising ways of inhibiting the transduc-
tion signal via EGFR are low molecular tyrosine
phosphorylation inhibitors (tyrphostins), recently
developed as synthetic tyrosine kinase inhibitors by
Levitzki [6] and Levitt [7]. These compounds can also
be a useful tool in investigations of autocrine growth
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regulation of cancer cell lines. In the present work,
we tested two tyrphostins: AG494 and AG1478 in the
autocrine growth regulation of human non small cell
lung cancer cells (NSCLC; A549; derived from can-
cerous lung tissue) and human prostate cancer cells
(DU145; derived from brain metastasis). Both the
investigated compounds are specific ATP-competitive
inhibitors of tyrosine kinase, located in the intracel-
lular domain of the EGFR. However, tyrphostin
AG1478, unlike AG494, acts in a non-reversible man-
ner [6, 8, 9]. Also, AG1478 structurally is very similar
to clinically used erlotinib (TarcevaTM) and gefitinib
(IressaTM), which implies it has a potent anti-cancer
application. We tried to evaluate the tyrphostins’ in-
fluence on proliferation, viability and signaling path-
way via EGFR, ERK and Akt protein kinases.
Materials and methods
Chemicals and reagents. Dulbecco’s modified minimal es-
sential medium (DMEM), minimal essential medium
(MEM), fetal bovine serum (FBS), 10,000 IU/ml penicillin
and 10 mg/ml streptomycin were purchased from PAA Lab-
oratories GmbH, Austria. Bovine serum albumin (BSA),
transferrin, trypsin, taxol, Hoechst No 33342, Crystal Vio-
let, propidium iodide (PI) and tyrphostins: AG494 and
AG1478 (kinase inhibition IC50: 1.2 µM and 3 nM, respec-
tively, values were taken from the manufacturer’s leaflets),
dimethyl sulfoxide (DMSO), ethylenediaminetetraacetic
acid (EDTA), (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltet-
razolium bromide (MTT) were obtained from Sigma (St.
Louis, MO, USA). Other reagents were provided by POCh
(Gliwice, Poland). ERK CASE Kit and Akt CASE Kit were
purchased from SABiosciences (Valencia, CA, USA). Stock
solutions of the tyrphostins were prepared by dissolving the
compounds in dimethylsulfoxide (DMSO) to a final con-
centration of 50 mM and storing the resultant solutions at
–20°C. DMEM/F12 (1:1) medium was used to dilute stock
solutions to working concentrations (AG494: 1–20 µM and
AG1478: 0.1–8 µM).
Cell culture. DU145 (HTB-81) and A549 (CCL-185) cells
were obtained from the American Type Culture Collection
(ATCC) and cultured in MEM or DMEM, supplemented
with 100 IU/ml penicillin and 100 µg/ml streptomycin in the
presence of 10% fetal bovine serum (FBS) and non essen-
tial amino acids (NEAA). The cells were passaged two or
three times per week.
Cell proliferation assays. Target cells were seeded on
96-well plates at concentrations of 4 × 103 cells/well in MEM
(DU145 cells) or DMEM (A549 cells), supplemented with
100 IU/ml penicillin and 100 µg/ml streptomycin in the pres-
ence of 10% FBS. Following 24 h of incubation, the culture
medium was replaced with serum-free DMEM/F12 (1:1)
supplemented with transferrin (5 mg/ml), sodium selenite
(2 ng/ml) and albumin (0.5 mg/ml) [DMEM/F12+]. After
an additional 24 h of incubation (Day 0), the medium was
replaced by serum-free DMEM/F12+ medium containing
tyrosine kinase inhibitors: AG494, AG1478 respectively in
concentration ranges 1–20 µM and 0.1–8 µM. The incuba-
tion was continued for the next 24 h at 37°C in a humidified
atmosphere. The modified crystal violet staining method
(CV) [10] and MTT assay [11] were used to determine the
influence of the tyrphostins on the proliferation of target
cells. The absorbance was measured using a Tecan (Spectra
Fluor Plus) multiscan plate recorder. Ten replicate wells
were used for each experiment. The effect of tyrosine ki-
nase inhibitors was expressed as a relative (to the controls)
decrease in cell growth determined after 48 h of incubation
with the investigated compounds. The calculated parame-
ter was:
where: Gi — growth inhibition, A — average values of ab-
sorbance: control at the start of experiments (A0), and after
the time of incubation without (Ak ) and with (Ai) the inves-
tigated compounds.
Assessment of cell viability. The double staining method
(Hoechst 33342/PI) [12] was used in the investigation of the
effect of tyrphostins AG494 and AG1478 on the viability of
A549 and DU145 cells. The cells were seeded on 48-well
plates at a density of 8 × 103/well in 0.45 ml DMEM or
MEM with 10% FBS. Following 24 h of incubation, the
culture medium was replaced with serum-free DMEM/
/F12+ medium. After an additional 24 h of incubation, the
cells were exposed to investigate tyrphostins in concentra-
tions previously outlined as IC10, IC50, IC90 and 20 nM of
taxol (positive control). The experiment was carried out
for 24 h and then Hoechst 33342 and propidium iodide
were added to the final concentration of 5 µg/ml and
1 µg/ml, respectively. After 25 min, the cells were directly
examined on plates with a fluorescent Olympus IMT 2 mi-
croscope. One excitation filter (for UV light) was used,
which allowed for excitation of both dyes. Image J soft-
ware was used for image processing (merging RGB chan-
nels, enhancing contrast and sharpening) and the quanti-
tative analysis of the processed pictures (cell counting). It
allowed for estimating the fraction of dead cells (PI/DNA
signal), viable cells (Hoechst 33342/DNA signal), and ap-
optotic cells (Hoechst 33342/DNA signal with morpholog-
ical changes characteristic of late-phase apoptosis). Each
experiment was repeated at least six times. Images with
the number of cells exceeding approximately 100 were se-
lected for the analysis.
Cell cycle analysis. To estimate the proportion of cells in
various phases of cell cycle, cellular DNA contents were
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measured by flow cytometry (FACS). DU145 cells
(2.5 × 105/dish) were plated on a Petri dish (Ø 6 cm) in
MEM supplemented with 10% FBS and sodium pyruvate
(MEM-NEAA). A549 cells in turn (2 × 105/dish) were plat-
ed on a Petri dish in DMEM supplemented with 10% FBS.
Both cell lines were allowed to attach overnight. Subsequent-
ly, the cells were placed in DMEM/F12+ and incubated for
another 24 h. After this time, tyrphostins AG494 and
AG1478 in concentrations previously outlined as IC50 and
IC90 were added to the investigated cell lines. 48 h after the
addition of the tyrphostins, the cells were harvested by
trypsinization and centrifuged. The pellets were suspended
in 1.0 ml of cold PBS with 2% FBS and washed twice. The
centrifuged pellets were suspended in 70% ethanol, fixed
at 4°C for 2 h and centrifuged (7 min at 280 × g; 1200 RPM).
The pellets were then re-suspended in 5 ml of PBS with 2%
FBS and centrifuged again. The cells were stained with
1 ml of propidium iodide (PI) solution (1 mg of RNAse A,
0.1 mg PI, 5 µl Triton X-100). Each sample was incubated at
37°C for 30 min. DNA content was determined  using
a FACScan Beckton-Dickinson flow cytometer.
Evaluation of activity of ERK and Akt. To determine the
influence of the investigated tyrphostins on the inhibition
of kinase activity of signal molecules (ERK and Akt), we
used the cell based CASE (Cellular Activation of Signaling
ELISA) test. Two kinds of primary antibodies were em-
ployed: one antibody recognized only the activated (phos-
phorylated) form of the specific target protein, while the
other recognized the specific target protein regardless of its
activation state. The target cells were seeded on 96-well
plates at a density of 5 × 103 cells/well in MEM (DU145
cells) or DMEM (A549 cells), supplemented with 100 IU/ml
penicillin and 100 µg/ml streptomycin in the presence of
10% FBS. Following 24 h of incubation, the culture medi-
um was replaced with serum-free DMEM/F12+. After an
additional 24 h of incubation, the medium was replaced with
serum-free DMEM/F12+ medium containing tyrosine ki-
nase inhibitors: AG494, AG1478 in a concentration previ-
ously outlined as IC90 in four repetitions; while in the con-
trol wells, we replaced the culture medium with fresh
DMEM/F12+. After three, six, 12 and 24 h, the cells were
fixed with a solution of 4% formaldehyde in PBS. Then we
continued the experiment according to the protocol [13]
which was shipped by the kit manufacturer. We introduced
a minor modification to the protocol, which involved time
extensions of the incubation with blocking buffer (until
5 h), primary antibody (until 12 h) and secondary antibody
(until 2 h).
Statistical analysis. Statistical analysis was performed with
the use of the GraphPad Prism 5.0 program. The effects of
different tyrphostin concentrations on DU145 and A549
cells proliferation were analyzed using one way ANOVA,
followed by Dunnett’s test. The Mann–Whitney U test was
used to determine differences in the percentage of alive,
apoptotic and necrotic cells in the control sample versus
tyrphostins or taxol (paclitaxel) treated samples. In the
CASE method, statistical analysis was performed with the
use of Statistica 9 program. The effects of EGFR inhibitors
on phosphorylation of signal molecules Akt and ERK were
analyzed using Fisher’s test. Differences were considered
significant at p < 0.05.
Results
Effect of tyrphostins AG494 and AG1478 on
DU145 and A549 cell proliferation
Human prostate cells DU145 and human lung can-
cer cells A549 were exposed for 48 h to tyrosine ki-
nase inhibitors, added at the concentration range of
1–20 µM (AG494) and 0.1–8 µM (AG1478). Three
repetitions were performed for each method. The
effect of the investigated tyrphostins determined by
CV and MTT assay is shown in Figure 1. The expo-
sure of DU145 and A549 cells to tyrphostin AG494
and AG1478 resulted in a significant dose-dependent
suppression of proliferation compared to the control
cultures. Autocrine growth of the investigated cells,
determined by the CV and MTT method, was practi-
cally completely inhibited at an AG494 concentration
≥ 15 µM in A549 cells and ≥ 20 µM in DU145 cells.
Similarly, the growth of prostate cancer cells was com-
pletely inhibited at a concentration of AG1478 ≥ 8 µM.
In turn, the growth inhibition curve of A549 cells
showed a plateau at an AG1478 concentration ≥ 2 µM.
The number of cells decreased to about 40% of
control.
A 10%, 50% and 90% inhibition of the growth of
A549 and DU145 cells was determined by fitting
a sigmoidal model of the dose-dependent effect of
the investigated tyrphostin (Table 1). IC10, IC50 and
IC90 coefficients calculated from the growth inhibi-
tion curves (Figure 1) after 48 h of incubation were
placed in Table 1. Due to the plateau on the growth
inhibition curve of A549 cells treated with AG1478,
it was impossible to calculate the IC90 value. Thus, in
further experiments, we assumed a 90% inhibition of
growth to be represented by the highest used con-
centration of EGFR inhibitor i.e 8 µM.
The results showed a higher cytostatic activity of
tyrphostin AG494 in the case of A549 cells and a sim-
ilar cytostatic activity of AG1478 in both of the inves-
tigated cell lines. The anti-proliferative activity (de-
scribed by IC50) was higher than that parameter out-
lined in the producer’s leaflet. In the case of AG494,
IC50 was about five (A549 cells) or eight (DU145 cells)
times higher, while in the case of AG1478, it was 300
times higher, regardless of the cell line.
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Effect of EGFR inhibitors on A549
and DU145 cell viability
The investigated tyrosine kinase inhibitors were also
examined for their cytotoxic potential and the ability
to induce tumor cell apoptosis or necrosis. As a pos-
itive control, the anti-neoplastic and anti-mitotic drug
paclitaxel was used. Paclitaxel has been examined as
a cytotoxic agent on various human cancer cell lines
[14, 15]. This taxane derivative binds to the tubulin
and stabilizes microtubules, arresting the cell cycle at
the G2/M phase. The microtubule damage induces
apoptosis [16]. The influence of tyrphostins AG494
and AG1478 on target cell viability was assessed af-
ter double-staining with Hoechst 33342 and propidi-
um iodide. Viable cells were stained on dark blue with
oval nuclei (gray in the black and white picture), ap-
optotic — light-blue (light gray in the picture) and ne-
crotic cells — red (white in the picture). Apoptotic cells
were clearly distinguishable by their characteristic
morphology (cytoplasmic blebbing, cell shrinkage, nu-
clear condensation and fragmentation, the so-called
apoptotic bodies) (Figure 2). The results of quantita-
tive determination of the number of viable, apoptotic
and necrotic cells are presented in Figure 3.
Both the investigated receptor kinase inhibitors
affected the viability of DU145 cells in a similar man-
Table 1. Values of IC10, IC50 and IC90 obtained from inhibitor curves of AG494 and AG1478
Cell line Tyrphostin AG494 [µM] Tyrphostin AG1478 [µM]
IC10 IC50 IC90 IC10 IC50 IC90
A549 2.04 ± 1.31 6.20 ± 1.26 11.80 ± 3.76 0.23 ± 0.18 1.16 ± 0.69 –
DU145 4.49 ± 2.73 10.7 ± 2.5 18.4 ± 6.43 0.01 ± 0.59 1.17 ± 0.61 12.7 ± 2.72
Figure 1. The dose-dependent effect of tyrphostins: AG494 (A) and AG1478 (B) on the growth of A549 and DU145 cells
after 48 h of incubation in serum-free DMEM/F12+ medium. Each point is the average of the values determined by MTT
and CV assay. Gi — growth inhibition; C — concentration of used compound
Figure 2. A typical picture of the cultures of DU145 cells
after 24h of incubation with 20 nM taxol. 1 — viable cells;
2 — apoptotic cells; 3 — necrotic cells. Magnification × 200
ner after 24 h of incubation in the serum-free medi-
um, while A549 cells seemed to be more sensitive to
AG494. In the case of the control culture of DU145
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and A549 cells, the number of apoptotic cells did not
exceed 7.68 ± 0.64% and 0.88 ± 0.23% of the entire
cell population respectively, while the number of ne-
crotic cells was about 2.82 ± 0.72%.
The viability of DU145 cells cultured with AG494
and AG1478 was in the range 75.7–77.76% of the
entire cell population, regardless of the kind of tyr-
phostin used. The percentages of apoptotic cells af-
ter incubation with AG494 and AG1478 increased to
21.32 ± 2.07 and 21.5 ± 1.11%, respectively. The
number of necrotic cells differed, from 0.91 ± 0.34%
in the case of AG494, to 2.8 ± 0.63% in the case of
AG1478. The comparison of these results with the
effect of 20 nM taxol (32.4 ±  4.51% of apoptotic and
11.78 ± 4.85% of necrotic cells) indicated that both
investigated tyrphostins, used in the concentrations
18.4 µM (AG494) and 12.7 µM (AG1478), were weak-
ly cytotoxic for DU145 cells. The number of apoptot-
ic and necrotic cells after DU145 incubation with both
tyrphostins was similar. In contrast, in lung cancer
cells treated with AG494 and AG1478, significantly
lower viability than in the case of prostate cancer cells
(respectively 55.35 ± 1.85 and 70.03 ± 2.33%) was
observed. Furthermore, the number of apoptotic and
necrotic cells differed from 23.81 ± 2.08% and 6.16 ±
± 1.23 in the case of AG1478, to 39.68 ± 1.54% and
4.97 ± 4.94% in the case of AG494. The proapoptotic
effect caused by AG494 in A549 cells was similar to
20 nM taxol (37.74 ± 1.21% of apoptotic and 7.66 ±
± 1.44% of necrotic cells).
Influence of AG494 and AG1478
on cell cycle of DU145 and A549 cells
DNA content of DU145 and A549 cells was deter-
mined by the use of a flow cytometer FACScan Beck-
ton-Dickinson after 48 h of incubation with the in-
vestigated compounds. The results are summarized
in Table 2. Opposite differences compared to the con-
trol cell culture were observed after DU145 and A549
treatment with the investigated tyrphostins. Non-re-
versible AG1478 acted more strongly on the prostate
cancer cell line than reversible AG494. This was un-
like with lung cancer cells, where the situation was
exactly the opposite. The increase in the number of
cells in the G1 phase in DU145 was about 4% and
18% respectively after AG494 and AG1478 treatment,
while the fraction of cells synthesizing DNA decreased
by about 60% (only in the case of AG1478). In A549,
unlike DU145, the increase in the number of cells in
the G1 phase was much lower — 4% in the case of
AG494 and only 2% in the case of AG1478, while the
number of cells in the S phase decreased by about 20%.
The proportion of cells in phases G1 to G2 changed
from 4.3 (control in DU145) to 5.5 in the case of
AG494, and 8.0 in the case of AG1478 and, respec-
tively, in A549 from 14.7 to 17.8 and 20.8 (Table 2).
Evaluation of ERK and Akt activity
in target cells treated with AG494 and AG1478
Cell-based ELISA technique showed that AG494 had
no influence on the level of phosphorylated ERK in
both investigated cell lines. By contrast, AG1478
caused a significant decrease of ERK phosphoryla-
tion in A549 and DU145 cells and the effect was time-
dependent (Figures 4C, D). In prostate cancer cells
treated with AG1478, phosphorylation of ERK de-
creased after 24 h of incubation to a value of 0.59
(the control value was equal to 1), but in lung cancer
cells the effect was reversible (after 24 h the activity
of ERK returned to the control value). After 3 h of
incubation, both tyrphostins  stimulated phosphory-
























































































Figure 3. The cytotoxic effect of tyrphostins: AG494, AG1478 and taxol (as the positive control) in A549 (A) and DU145
cells (B), after 24 h of incubation in DMEM/F12+ medium. The average percentage of: viable cells (gray), apoptotic cells
(white) and necrotic cells (black). Statistical significance: ***p < 0.001; *0.01 < p < 0.05; NS — not significant
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an evident decline of activation of that protein observed
(with a stronger effect for AG1478) (Figure 4B).
The investigated tyrphostins exerted an opposite
effect on A549 cells — AG494 at first excited the phos-
phorylation of Akt and then highly inhibited this
process, but AG1478 initially strongly inhibited the
phosphorylation of Akt and even after 24 h, the ac-
tivity of that protein did not exceed the control value
(Figure 4A)
Discussion
It is widely accepted that autocrine growth regula-
tion is at least partly responsible for the development
of cancer. Dysregulation of EGFR activation is im-
plied in numerous human cancers (e.g. brain, lungs,
breast and prostate) [17, 18]. Oncogenic activation
of EGFR may have diverse origins, and one of the
mechanisms is overexpression of growth factors and
its receptors. EGF/EGFR or TGFa/EGFR autocrine
loops are well documented in both lung and prostate
cancer cells [1, 2, 19]. The A549 cells exhibit overex-
pression of wtEGFR (80%) [3] while DU145 mainly
mutated EGFRvIII [3, 20, 21]. According to the above
features, we used these lung and prostate cancer cell
lines as a model of EGFR-induced cancer.
Various approaches have been used to inhibit or
down-regulate neoplastic growth of prostate and lung
cancer using taxol, genistein, erbstatin, soluble recep-
tors, pseudoligands, monoclonal antibodies for ty-
rosine kinase receptors and synthetic receptor tyrosine
kinase inhibitors (tyrphostins). We compared the ac-
tivity of two tyrphostins: AG494 (reversible) and
AG1478 (non-reversible) on the growth of A549 and
DU145 cell lines.
The results described in this paper indicate that
the blockade of EGFR signaling pathways by tyr-
phostins AG494 and AG1478 inhibits proliferation
and viability of the investigated cells in vitro. IC50 de-
termined by two different methods was similar for
tyrphostin AG1478 (1.16–1.17 µM) independent of
the kind of investigated cells, and differed slightly for
AG494 (6.16 µM in A549 and 10.7 µM in DU145
cells). The obtained data suggests that the EGF/TGFa
autocrine loop induces a specific signaling route,
which determines the cell’s fate. Our results indicate
that AG494 at a concentration > 15 µM is able to
completely inhibit A549 and DU145 autocrine cell
growth, in contrast to tyrphostin AG1478 which when
used at a concentration ≥ 2 µM decreased cell growth
of A549 to 40% of control. This could be caused by
several factors. First of all, AG1478 has a higher af-
finity to mutated forms of EGF receptor, overex-
pressed in DU145 cells [3, 22, 23]. Therefore, prolif-
eration of DU145 cells (which exhibit overexpression
of EGFRvIII) [20, 21] after AG1478 treatment was
almost completely inhibited. The second possibility
is a heterogeneous population of lung cancer cells,
with partial resistance to the used compound. Resis-
tance to AG1478 might be caused by a multi-drug re-
sistance mechanism (which has been described in
many patients with lung cancer [24]) in A549 cells.
The anti-proliferative activity (described by IC50)
was higher than that parameter outlined in the pro-
ducer’s leaflet. In the case of AG494, IC50 was about
five (A549 cells) or eight (DU145 cells) times higher,
while in the case of AG1478 it was 300 times higher,
regardless of the cell line. Probably IC50 coefficient in
producer’s leaflet was obtained for an isolated form
of EGFR kinase. The investigated tyrphostins act like
ATP competitors. Inside living cell concentration of
ATP is relatively high, so ATP itself could alter inter-
action between tyrphostin and EGFR kinase. As
a result higher concentrations of EGFR inhibitors are
required in cells. Then, tyrphostins are able to effec-
tively bind to ATP-binding pocket in the kinase do-
main of the receptor. This process in turn prevent
from ATP binding and receptor activation.
The main difference in the effect of AG494 and
AG1478 is the different kinetics of A549 cell growth
inhibition. This data suggests various mechanisms of
growth inhibition. That hypothesis was only partly
supported by the results of the effect of the investi-
gated tyrphostins on the phosphorylation of some sig-
Table 2. The effect of AG494 and AG1478 on the proportion of DU145 and A549 cells in various phases of cell cycle.
Cellular DNA contents were measured by flow cytometry (FACS) after 48h of incubation with the tyrphostins
Phase of % of cellular DNA in DU145 cells % of cellular DNA in A549 cells
cell cycle Control AG494 IC50 AG494 IC90 AG1478 IC50 AG1478 IC90 Control AG494 IC50 AG494 IC90 AG1478 IC50 AG1478 IC90
G1 62.6 66.1 66.1 73.0 80.5 76.6 77.0 81.0 78.1 78.2
G2 14.5 13.8 12.6 13.3 10.0 5.2 5.1 4.6 4.6 3.8
S 22.9 20.0 21.3 14.7 9.5 18.2 18.0 14.5 17.4 17.9
G1:G2 4.3 4.8 5.3 5.5 8.0 14.7 15.1 17.8 17.0 20.8
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Figure 4. Time-dependent influence of tyrphostins AG494 and AG1478 on phosphorylation of signal molecules in target cell
lines. The activity of Akt and ERK after treatment with investigated tyrphostins is shown in relation to their activity in the
controls. Only points with statistical significance were marked as follows: ***p < 0.001; **0.001 < p < 0.01; *0.01 < p < 0.05
nal proteins. The results obtained from the CASE test
could prove that AG494 does not affect the activity
of ERK (no effect on protein phosphorylation in both
target cells was observed), which is supported by the
available literature data [9]. Despite the fact that
AG1478 does not show complete inhibition of growth,
it significantly inhibits the activity of ERK in both cell
lines (more strongly in DU145 cells). Most likely this
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is due to the fact that AG1478 inhibits the activity of
Src, which in turn may be involved in further activa-
tion of the MAP cascade [25, 26, 28]. This kinase is
involved in the signaling responsible for mitosis, ad-
hesion, invasiveness, motility and progression of can-
cer cells [19, 25–27]. Src can directly interact as a sub-
strate or activator with active EGFR. After activa-
tion, it may in turn phosphorylate EGFR, which leads
to an increase in the activity of receptor’s tyrosine
kinase (positive feedback coupling) [26, 28]. A de-
crease in ERK activity can inhibit cell proliferation
by a lack of adequate stimulation of cyclin-dependent
kinases [1, 30, 31] or transcription factors (c-fos,
c-myc, c-jun) [32]. The impact of target inhibitors on
the phosphorylation of Akt is dependent on cell line.
In the case of lung cancer cells, we observed (after
6 h of incubation) a higher decrease in activity than
in prostate cancer cells for each of the investigated
tyrphostins. Inhibition of the phosphorylation of the
Akt may on the one hand cause apoptosis (e.g. lack
of inactivation of the pro-apoptotic protein Bad), and
on the other hand, inhibition of proliferation (such
as induction of the p-53 protein responsible for cell
cycle arrest) [30, 33]. In prostate cancer cells, the ac-
tivity of Akt and ERK even after 24 h did not exceed
the control value, while in lung cancer it did. This may
be caused by the presence in A549 cells of additional
autocrine loops [1, 2, 19]. For example, the TGFa/
/EGFR autocrine loop can induce the production of
VEGF within the lung cancer cell, which in turn leads
to activation of signalization via VEGFR [34, 35].
Then even the blockade of EGFR activity by investi-
gated tyrphostins does not alter the activity of signal
molecules like Akt and ERK. This may be the mech-
anism by which cells are able to find alternative sig-
naling pathways. The described phenomenon could
explain the curve plateau of growth inhibition caused
by AG1478 in A549 cells. Induction of VEGFR by
TGFa/EGFR autocrine loop leads to phosphoryla-
tion of ERK. Thus, blockade of EGFR activity by
AG1478 in lung cancer cells is an insufficient factor
to inhibit proliferation of these cells.
The differential staining method showed that the
investigated tyrphostins, used at concentrations £ 18
µM (AG494) and £ 13 µM (AG1478), had little ne-
crotic effect on the DU145 cell line, and indeed in
the case of the A549 cell, this process was not ob-
served. However, both investigated tyrphostins in-
creased significantly the number of apoptotic cells.
Further experiments have revealed that both the in-
vestigated inhibitors increased the percentage of
DU145 and A549 cells in S phase of cell cycle, indi-
cating that AG494 and AG1478 arrest cell growth in
the G1 phase, similarly to other known inhibitors of
EGFR [9, 36, 37]. Furthermore, cell growth arrested
in the G1 phase after tyrphostins treatment could lead
cancer cells to an apoptotic pathway.
Our results indicate that each of the investigated
tyrphostins works differently, both within a single cell
line and between the different cell lines. The influ-
ence of the inhibitors on the same cell line differs
(despite similar mechanism of action — ATP com-
petitors) [37–39] perhaps because they belong to dif-
ferent chemical classes. Reversible AG494 is ben-
zylidene malonitrile [40] and non-reversible AG1478
is anilinoquinazoline [41], with the resulting small
differences in chemical structure of the compound.
This may cause the difference in a cell’s membrane
permeability against these inhibitors.  Moreover, slight
differences in chemical structure alter properties of
each tyrphostin to bind to ATP binding pocket. This
could be the reason for different kinetics of growth
inhibition among both EGFR inhibitors. Our further
experiments showed that AG494 and AG1478 act in
a reversible manner [data not shown]. After replace-
ment with inhibitor free medium, reinitiation of cell
growth was observed, regardless of the concentration
of investigated tyrphostins. Thus, the description giv-
en by Levitzki and Levitt of the reversibility and irre-
versibility of certain tyrphostins may be evaluated only
according to the inhibition of enzyme activity in a non
cellular environment. However, it is a well-document-
ed fact that the action of the inhibitor is dependent
on the cell line [42–49]. This may be due to the pres-
ence of different mutations in the intracellular signal
transduction machinery. One example is the fact that
AG1478 has a higher affinity for mutant forms of the
receptor (e.g. EGFRvIII) [22, 23] than the wild type
form; therefore, the cells with wtEGFR (e.g. A549
cells) [3] will show a weaker growth inhibition after
AG494 treatment than in the case of AG1478. Un-
equivocal interpretation of obtained results is diffi-
cult, because the growth, survival and other features
of both investigated cells are regulated by several
autocrine loops [1, 2, 19].
Summary
The effect of tyrphostins AG494 and AG1478 on lung
and prostate cancer cell growth is dose dependent.
Non-reversible tyrosine kinase inhibitor AG1478 is
stronger cytostatically than reversible inhibitor AG494
for target cell lines (IC50 of AG1478 is five times low-
er). Despite the similar mode of action (ATP com-
petitors), the investigated tyrphostins act differently
within the same cell line; moreover, the activity of
AG494 and AG1478 may vary depending on the cell
line. Both kinase inhibitors have a strongly proapop-
totic effect in A549 and DU145 cells without cell ne-
crosis. Blockade of only one family of receptors
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(EGFR) is an insufficient factor to the simultaneous
inhibition of MAP and PKB/Akt kinase cascades.
Abbreviations used
EGF — Epidermal Growth Factor; EGFR — Epi-
dermal Growth Factor Receptor; ERK — Extracel-
lular Regulated Kinase; PKB (Akt) — Protein Kinase
B; TGFa — Transforming Growth Factor alpha
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